Companies / Belgium
EU Approval For UCB's IV Keppra
April 2006 | Product LaunchThe European Commission has approved Belgium company UCB's intravenous (iv) formulation of Keppra (levetiracetam) for the treatment of partial-onset seizures.
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
